Mixing wilate® with nextaro®
Reconstitute wilate® powder concentrate immediately before injection in a clean environment and use the solution within 4 hours. The process to mix the solution with the nextaro® transfer device is simple and straightforward. Just follow these 8 easy steps:
-
Prepare the vials
Remove the caps from the wilate® concentrate vial and water vial and clean the rubber stoppers with an alcohol swab.
-
Open nextaro®
Open the nextaro® transfer device package by peeling off the lid.
Leave the nextaro® device in the clear outer packaging and avoid touching the device to keep it clean.
-
Attach nextaro® to water vial
Hold the water vial firmly on a hard, level surface. With nextaro® still in the outer packaging, turn it upside down and push the blue part straight and firmly down on the water vial until it snaps into place.
Do not twist while attaching.
Note: nextaro® must be attached to the water vial first. Otherwise, there will be a loss of suction, and the water will not flow into the wilate® vial.
-
Attach the wilate® vial
Carefully remove the outer package from the nextaro® transfer device.
With the wilate® vial held firmly on a hard, level surface, flip the water vial with the attached transfer device upside down and secure the white part of the transfer device to the wilate® vial by pressing on it until it snaps into place.
The water will be drawn into the wilate® vial by the vacuum.
-
Swirl the connected vials
With both vials still attached, immediately start to gently swirl the connected vials to ensure that the powder is fully saturated.
Do not shake.
-
Detach nextaro®
After swirling for 30 seconds, firmly hold the white and blue parts of the nextaro® transfer device. Unscrew nextaro® counterclockwise into two separate pieces.
Discard the empty water vial and blue part of the transfer device.
-
Continue swirling
Without touching the connector, continue swirling the wilate® vial until the powder has fully dissolved. This process may take several minutes.
The final solution is clear or slightly opalescent, colorless, or slightly yellow. Reconstituted product should be inspected visually for particulate matter.
-
Prepare for infusion
Use a syringe to draw out the reconstituted product.
Do not use if the powder fails to dissolve or any solids are formed.
- 1
wilate® Full Prescribing Information. Paramus, NJ: Octapharma; rev July 2026.
Indications and Important Safety Information for wilate® [von Willebrand Factor/Coagulation Factor VIII Complex (Human)].
Please see wilate® full Prescribing Information.
Indication
wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in adult and pediatric patients with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes. wilate® is also indicated in adult and pediatric patients 12 years of age and older with hemophilia A for on-demand treatment and control of bleeding episodes; and for routine prophylaxis to reduce the frequency of bleeding episodes.
Contraindications
Do not use in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reaction, to human plasma-derived products, any ingredient in the formulation, or components of the container.
Warnings and Precautions
- Anaphylaxis and severe hypersensitivity reactions are possible
- Thromboembolic events may occur. Monitor plasma levels of FVIII activity
- Neutralizing antibodies (inhibitors) to VWF and Factor VIII have occurred following administration of wilate®. Test for neutralizing antibodies if plasma VWF and/or Factor VIII level fail to increase as expected or if bleeding is not controlled after wilate® administration
- wilate® is made from human plasma and carries the risk of transmitting infectious agents
Adverse Reactions
The most common adverse reactions (≥ 1%) in clinical trials on VWD were hypersensitivity reactions, urticaria, chest discomfort, and dizziness. The most common adverse reaction (≥ 1%) in clinical trials in hemophilia A was pyrexia (fever).
Please see wilate® full Prescribing Information.
Indications and Important Safety Information for wilate® [von Willebrand Factor/Coagulation Factor VIII Complex (Human)].
Please see wilate® full Prescribing Information.
Indication
wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in adult and pediatric patients with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes. wilate® is also indicated in adult and pediatric patients 12 years of age and older with hemophilia A for on-demand treatment and control of bleeding episodes; and for routine prophylaxis to reduce the frequency of bleeding episodes.
Contraindications
Do not use in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reaction, to human plasma-derived products, any ingredient in the formulation, or components of the container.
Warnings and Precautions
- Anaphylaxis and severe hypersensitivity reactions are possible
- Thromboembolic events may occur. Monitor plasma levels of FVIII activity
- Neutralizing antibodies (inhibitors) to VWF and Factor VIII have occurred following administration of wilate®. Test for neutralizing antibodies if plasma VWF and/or Factor VIII level fail to increase as expected or if bleeding is not controlled after wilate® administration
- wilate® is made from human plasma and carries the risk of transmitting infectious agents
Adverse Reactions
The most common adverse reactions (≥ 1%) in clinical trials on VWD were hypersensitivity reactions, urticaria, chest discomfort, and dizziness. The most common adverse reaction (≥ 1%) in clinical trials in hemophilia A was pyrexia (fever).
Please see wilate® full Prescribing Information.
You Are Now Leaving wilateusa.com
Octapharma does not review, endorse, or control the content of any non-Octapharma site. Octapharma is not responsible for the accuracy, content, practices, or standards of any non-Octapharma resources accessed through a link on this site. Octapharma provides general information for educational purposes. This site does not provide medical advice, diagnosis, or treatment to you. Always consult your physician to help decide a treatment plan or other medical advice.
FOR U.S. HEALTHCARE PROFESSIONALS ONLY
The information on this website has been specifically created for U.S. healthcare professionals (HCPs)
Please see wilate® full Prescribing Information